Indeed, FGF21-analogons administered to patients with obesity and T2D resulted in weight loss, lower low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), higher high-density lipoprotein cholesterol (HDL-C), but also higher blood pressure. The gene discussed is FGF21; the disease is obesity disorder.